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Edited by Gerrit van MeerAbstract P-glycoprotein is an eﬄux pump for a broad
spectrum of hydrophobic agents. We found that bioactive
peptides including somatostatin and substance P inhibit ATP-
dependent vincristine binding to P-glycoprotein-overexpressing
K562/ADM membrane vesicles. Some of these bioactive peptides
including somatostatin stimulate basal ATPase activity of
P-glycoprotein; in contrast, other peptides including substance
P inhibit it. The K562/ADM membrane vesicles showed an ATP-
dependent, osmotically sensitive uptake of somatostatin and
substance P, which was inhibited by valspodar, an inhibitor of P-
glycoprotein. These ﬁndings suggested that certain bioactive
peptides such as somatostatin and substance P directly interact
with human P-glycoprotein as endogenous substrates for P-
glycoprotein-mediated transport.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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P-glycoprotein, a 170–180-kDa membrane glycoprotein, is a
member of the adenosine 50-triphosphate (ATP)-binding cas-
sette transporter family. It has been well documented that
overexpression of P-glycoprotein mediates one type of multi-
drug resistance (MDR) in tumor cells [1,2]. This protein is
composed of two homologous subunits which contain 6
transmembrane segments and an ATP-binding cassette do-
main that catalyzes ATP hydrolysis [3–6]. Utilizing the energy
produced by the hydrolysis of ATP, P-glycoprotein actively
pumps out a broad spectrum of uncharged and positively
charged amphipathic agents, such as anthracyclines, epipod-
ophyllotoxins, steroids and short chain phospholipid ana-
logues. P-glycoprotein is present not only in tumor cells but
also in various non-tumorous epithelial tissues including ad-
renals, liver, kidney, intestine, placenta, pregnant uterus and
capillary endothelial cells of brain and testis [7]. The tissue
distribution pattern of P-glycoprotein and its known function* Corresponding author. Fax: +81-298-65-2385.
E-mail address: noriko.uchiyama@pharma.novartis.com
(N. Uchiyama-Kokubu).
Abbreviations: ATP, adenosine 50-triphosphate; MDR, multidrug
resistance; GRP, gastrin releasing peptide; LH-RH, luteinizing hor-
mone-releasing hormone
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doi:10.1016/j.febslet.2004.07.084strongly suggest the important physiological roles of P-glyco-
protein in the disposition of xenobiotics and drug metabolites
by a urinary excretion mechanism in the kidney, a biliary ex-
cretion mechanism in the liver absorption barrier, as well as a
blood–brain barrier mechanism that limits accumulation of
drugs in the brain [8].
In addition to the xenobiotics, various endogenous sub-
strates for P-glycoprotein-mediated transport have been in-
vestigated in normal tissues. One of the physiological
substrates for P-glycoprotein is steroid hormone in adrenal
cortex, gravid uterus and placenta. Several steroids, such as
aldosterone, corticosterone and cortisol are transported by P-
glycoprotein [9]. Orlowski et al. [10] showed that progesterone
and desoxycorticosterone stimulated P-glycoprotein-ATPase
activity. The observation that P-glycoprotein in the adrenal
gland has ATPase activity like those in the MDR cells [11]
suggests another physiological role of P-glycoprotein in se-
cretion of steroid hormones from normal tissues.
Gastrointestine functions as an important organ for endo-
crinology by secretion of peptide hormones, e.g., somatostatin
and substance P that are known as bioactive peptides with
diverse physiological functions. Within the gastrointestinal
tract, somatostatin works as a potent inhibitor of ﬂuid and
electrolyte secretion, primarily by activation of somatostatin
receptor [12]. Substance P is involved in the physiological
control of several digestive functions, including motility, ﬂuid
and electrolyte secretion, blood ﬂow and tissue homeostasis
[13,14]. Since P-glycoprotein is found in high concentrations
on the epithelial cells in gastrointestinal tracts [15], P-glyco-
protein may interact with those peptide hormones as endoge-
nous substrates. In the present study, we report that certain
bioactive peptides such as somatostatin and substance P are
the substrates for transport by human P-glycoprotein.2. Materials and methods
2.1. Materials and tumor cells
Bombesin, neuromedin B, neuromedin C, gastrin releasing peptide
(GRP, human), substance P, luteinizing hormone-releasing hormone
(LH-RH, human), dynorphin A (human), mastoparan, a-mating fac-
tor and Leu–Pro–Leu–Arg–Phe-NH2 were purchased from Peptide
Institute Inc. (Osaka, Japan). Somatostatin, creatine phosphate, cre-
atine kinase, ATP and vinblastine were purchased from Sigma (St.
Louis, MO). All peptides were dissolved in water and stored at )20 C.
Precast peptide-polyacrylamide gel electrophoresis (peptide-PAGE)
gels were from TEFCO (Tokyo, Japan). Anti-somatostatin mouse
monoclonal antibody was obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, California). Anti-substance P rat monoclonalblished by Elsevier B.V. All rights reserved.
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(Westbury, New York). Horseradish peroxidase-conjugated anti-
mouse and anti-rat IgG were purchased from Amersham Pharmacia
Biotech (Uppsala, Sweeden). ImmobilonTM Transfer Membranes
(0.45 lm pore size) were obtained from Millipore (Tokyo, Japan).
[prolyl2;4-3,4(n)-3H]Substance P ([3H]substance P, speciﬁc activity, 39
Ci/mmol), (3-[125I]iodotyrosyl11)-Try11-somatostatin-14 ([125I]somato-
statin, speciﬁc activity, 2000 Ci/mmol) and [G-3H]vincristine sulfate
([3H]vincristine, speciﬁc activity, 6.9 Ci/mmol) were purchased from
Amersham (Tokyo, Japan). The purity of the ligand was conﬁrmed by
using HPLC or TLC, [3H]substance P, [125I]somatostatin and
[3H]vincristine were 98.6%, >90% and 97.6% pure, respectively. Val-
spodar (PSC 833) was supplied by Novartis Pharma. Ltd. (Basel,
Switzerland) and was prepared as 10 mM stock solutions in 100%
DMSO.
Doxorubicin-resistant human mylogenous leukemia K562 (K562/
ADM) was established as previously described [16]. Cells were grown
on 100-mm plastic tissue culture plates (Corning Glass Works, Corn-
ing, NY) containing RPMI-1640 medium (Sigma, Tokyo, Japan)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and
antibiotic- and antimycotic-solution (GIBCO BRL, Rockville, MD) in
an atmosphere containing 5% CO2 at 37 C. The K562/ADM cells
were maintained in the presence of 0.5 lg/ml doxorubicin. Human
epidermoid carcinoma KB3-1 cell line and its transfectant with human
wild-type MDR1 cDNA (GSV-2) were generous gifts from I.B. Ron-
inson (Molecular Genetics, University of Illinois, Chicago). The cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium (GIBCO
BRL, Rockville, MD) supplemented with 10% heat-inactivated FBS
and antibiotic- and antimycotic-solution.
2.2. Preparation of plasma membrane vesicles
A plasma membrane-enriched fraction of the cells was prepared as
described previously [17,18]. Brieﬂy, cell suspensions of either K562/
ADM or K562 cells were centrifuged and resuspended in homoge-
nate buﬀer (10 mM Tris–HCl, pH 8.0, 75 mM sucrose, 25 mM
MgCl2, 1.5 mM ethylenediaminetetraacetic acid, 150 mM NaCl, 150
mM KCl, and 5 mM dithiothreitol (DTT)). The pellets were dis-
rupted by sonication for 30 s (Branson Soniﬁer model 450), and
unbroken cells and nuclei were removed by centrifugation at
1000 g for 5 min. The supernatants were laid onto a discontinuous
sucrose gradient consisting of 16%, 31% and 45% sucrose. Centri-
fugation was carried out using a SW41Ti rotor (Beckman) for 18 h
at 76 900 g at 4 C. The opaque band at the 16/31% interface was
collected and diluted with STM buﬀer (10 mM Tris–HCl, pH 7.5,
250 mM sucrose, 1.5 mM MgCl2, 20 lg/ml aprotinin and 1 mM
phenylmethylsulfonyl ﬂuoride). The fraction was sedimented and the
pellets were resuspended in STM buﬀer. The protein concentration
was determined by the Lowry method [19] with bovine serum al-
bumin as standard.
2.3. Preparation of P-glycoprotein-MRK-16–Protein A complexes
P-glycoprotein was immunoprecipitated with anti-P-glycoprotein
monoclonal antibody MRK-16 as described previously [4]. The
plasma membrane-enriched fractions from the K562/ADM cells were
dissolved in solubilizing buﬀer composed of 50 mM Tris–HCl, pH
7.5, 150 mM NH4Cl, 2 mM MgCl2 and 1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfate (CHAPS) and sujected to im-
munoprecipitation. The membrane lysate (0.75 mg protein) was in-
cubated with 20 lg of MRK-16 for 2 h at 4 C and then 100 ll of
Protein A–Sepharose CL4B suspension (20% by volume in solubi-
lizing buﬀer) was added to 1 ml of the membrane lysate and left for 1
h. The precipitates were washed ﬁve times with the reaction buﬀer (50
mM Tris–HCl, pH 7.5, 150 mM NH4Cl, 2 mM MgCl2 and 0.1%
CHAPS).
2.4. Substance P and somatostatin transport by P-glycoprotein
Uptake of [3H]substance P or [125I]somatostatin into membrane
vesicles was measured by the rapid ﬁltration technique. Brieﬂy,
plasma membrane vesicles (approximately 50 lg of protein) prepared
from K562, K562/ADM, KB3-1 or GSV-2 cells were added to a 200
ll of the transport assay solution containing 250 mM sucrose, 10
mM Tris–HCl, pH 7.0, 5 mM MgCl2, 10 mM creatine phosphate, 0.1
mg/ml creatine kinase, 5 mM ATP and the radio-labeled peptide at
the indicated concentration, which was pre-warmed at 37 C. After
incubation for the indicated time at 37 C, the vesicles were rapidlyﬁltered through nitrocellulose ﬁlters (0.45 lm pore, Schleicher and
Schuell, Dassel, FRG) and immediately washed with 5 ml of ice-cold
buﬀer (250 mM sucrose, 10 mM Tris–HCl, pH 7.0, and 1 mg/ml
albumin). The ﬁlters were dried and radioactivity was quantiﬁed by
liquid-scintillation counting. Non-speciﬁc binding of the tested pep-
tides to the ﬁlter was determined in the absence of membrane vesicles
and non-speciﬁc uptake into the vesicles was determined in the ab-
sence of ATP.
Initial transport of [3H]substance P or [125I]somatostatin was cal-
culated by incubation with various substrate concentrations; the data
were then ﬁtted to Michealis–Menten type equation
V ¼ Vmax  ½SðKm þ SÞ
in which Vmax is the maximal initial transport rate and Km is the
substrate concentration at which the transport rate reaches the half-
maximal value.
2.5. Binding assay
The ATP-dependent binding of [3H]vincristine to the membranes of
K562/ADM cells was examined in the presence or absence of bioactive
peptides. Binding of [3H]vincristine to membranes was measured by the
ﬁltration method as described previously [20]. Isolated plasma mem-
branes containing 100 lg of protein was incubated at 25 C with 250
nCi of [3H]vincristine in 10 mM Tris–HCl (pH 7.4), 250 mM sucrose, 5
mM MgCl2, and 3 mM ATP (buﬀer A) in a total volume of 100 ll.
After 5 min, the reaction was stopped by adding 4 ml of ice-cold buﬀer
A. The plasma membranes were collected by ﬁltration on a membrane
ﬁlter (Millipore MF-membrane, pore size 0.22 lm) pretreated with 3%
bovine serum albumin solution. The samples were then washed with
another 4 ml of ice-cold buﬀer A. By this method, approximately 60%
of the membrane proteins were recovered on the ﬁlter. The ﬁlters were
dried and radioactivity on each ﬁlter was measured.
2.6. P-glycoprotein ATPase assay
The P-glycoprotein-MRK-16–Protein A complexes were subjected
to the ATPase assay. The ATPase activity was estimated by a cou-
pled enzyme assay as described previously [21,22]. The immuno-
complexes were dissolved in buﬀer A (10 mM Tris–HCl, pH 8.0, 2
mM MgCl2, 10 mM NaCl, 10 mM KCl and 1 mM DTT) supple-
mented with 5 mM Mg2þ/ATP, 0.1 mg/ml pyruvate kinase, 1 mM
phosphoenolpyruvate, 0.1 mg/ml lactate dehydrogenase and 1 mM b-
nicotinamide adenine dinucleotide (NADH). The absorbance at 340
nm was monitored and the rate of NADH degradation was deter-
mined by linear regression. Statistical diﬀerence from the basal AT-
Pase activity was analyzed by ANOVA (Bonferroni/Dunn test;
StatView ver 4.02).
2.7. Protease protection experiments
Protease protection experiments were performed as described pre-
viously [23] with minor modiﬁcations. Brieﬂy, either K562/ADM or
K562 plasma membrane vesicles (approximately 50 lg of protein)
were added to a 200 ll pre-warmed (37 C) transport assay buﬀer
(250 mM sucrose, 10 mM Tris–HCl, pH 7.0 and 5 mM MgCl2, 10
mM creatine phosphate, 0.1 mg/ml creatine kinase, 5 mM ATP)
containing 250 lM somatostatin or 400 lM substance P (4 lg or 5.4
lg of total protein per transport reaction, respectively). After incu-
bation for 1 min at 37 C, the vesicles were washed with PBS (-). The
samples were treated for 2 h at 4 C with 250 units of trypsin in the
presence or absence of Triton X-100 (1% w/v) in 10 mM Tris–HCl
(pH 8.0). The reaction was terminated by adding a protease inhibitor
mixture followed by elution of the proteins using 2 · sample buﬀer
(0.2 M Tris–HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 40%
glycerol, 125 mM DTT and 0.04% Coomassie blue G-250) for pep-
tide–PAGE. The peptide separated by 16% peptide-PAGE was
transferred electrophoretically to Immobilon sheets and the immu-
noblot analysis was carried out as described previously [24]. Blots
were probed with 100-fold diluted anti-somatostatin mouse mono-
clonal antibody or anti-substance P rat monoclonal antibody for 1 h
followed by incubation with horseradish peroxidase-conjugated anti-
mouse or anti-rat IgG diluted 2000-fold. All bands were visualized by
SuperSignal West Femto Trial Kit (Pierce, Rockford, IL) using a
Luminescent Image analyzer LAS-1000 (Fujiﬁlm, Tokyo, Japan) and
an Image Reader LAS-1000 Pro (version 2.11 for Windows, Fujiﬁlm,
Tokyo, Japan).
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3.1. Inhibition of vincristine binding to K562/ADM membrane
vesicles by bioactive peptides
We examined the inhibitory activity of bioactive peptides on
the ATP-dependent binding of vincristine to K562/ADM
membrane vesicles to elucidate whether these peptides compete
for the vincristine binding sites of P-glycoprotein. Table 1
shows that substance P and somatostatin inhibited the vin-
cristine binding to K562/ADM membrane in the presence of
ATP with the IC50 value of 41 4.1 and 21 1.2 lM, re-
spectively (Table 1, means S.E. of three experiments).
We also examined the eﬀects of some peptide hormones and
a toxic peptide on vincristine binding. Nine bioactive peptides
(bombesin, neuromedin B, neuromedin C, GRP, LH-RH,
dynorphin A, mastoparan, a-mating factor and Leu–Pro–Leu–
Arg–Phe-NH2) eﬀectively inhibited the binding of vincristine
to K562/ADM membrane vesicles. The IC50 values were 3.6–
83 lM in the range for nine peptides tested. GRP inhibited the
vincristine binding most eﬃciently and showed the lowest IC50
values.Table 1
Eﬀects of bioactive peptides on the ATP-dependent binding of [3H]vincristin
Peptide Amino acid composition
Somatostatin A-G-C-K-N-F-F-W-K-T-F-T-S-C
Substance P R-P-K-P-Q-Q-F-F-G-L-M-NH2
Bombesin pE-Q-R-L-G-N-Q-W-A-V-G-H-L
Neuromedin B G-N-L-W-A-T-G-H-F-M-NH2
Neuromedin C G-N-H-W-A-V-G-H-L-M-NH2
GRP V-P-L-P-A-G-G-G-T-V-L-T-K-M
LH-RH pE-H-W-S-Y-G-L-R-P-G-NH2
Dynorphin A Y-G-G-F-L-R-R-I-R-P-K-L-K-W
Mastoparan I-N-L-K-A-L-A-A-L-A-K-K-I-L-
a-Mating Factor W-H-W-L-Q-L-K-P-G-Q-P-M-Y
Leu–Pro–Leu–Arg–Phe–NH2 L-P-L-R-F-NH2
The IC50 value is the concentration of the peptide which inhibites [
3H]vincrist
experiments. Aromatic amino acids are depicted in bold letters. pE: pyroglu
Fig. 1. Eﬀects of physiological bioactive peptides on the basal P-glycoprotei
hibitors, respectively. P-glycoprotein in the membrane fraction prepared fro
glycoprotein-MRK-16–Protein A–Sepharose complexes were subjected to t
bioactive peptides is expressed as a percentage of the basal ATPase activity of
mg P-glycoprotein). The concentrations of the bioactive peptides used were 1
triplicate experiments. Signiﬁcant diﬀerence from basal ATPase activity was d3.2. Eﬀects of physiological bioactive peptides on basal
P-glycoprotein ATPase activity
To examine the direct interaction of bioactive peptides with
P-glycoprotein, we studied the eﬀect of the peptides on the
basal ATPase activity of P-glycoprotein. P-glycoprotein was
immunoprecipitated with MRK-16 and the P-glycoprotein-
MRK-16–Protein A–Sepharose complexes were subjected to a
coupled enzyme ATPase assay. The immunocomplexes dem-
onstrated an ATPase activity of 102 11 nmol/min/mg P-
glycoprotein (means S.E. of three experiments). To validate
the ATPase assay for P-glycoprotein used in this study, we
examined the eﬀect of the presence of vinblastine which is
known as a substrate for P-glycoprotein-mediated transport
[25] and a stimulator of P-glycoprotein-ATPase activity [6]. As
demonstrated in Fig. 1A, vinblastine at 40 lM stimulated
ATPase of the immunocomplexes by 233%.
Somatostatin stimulated the basal ATPase activity approx-
imately 2-fold with a half maximum level (i.e., SC50) of 22 16
lM (means S.E. of three experiments) (Fig. 1A). Other
peptides such as bombesin, neuromedin B, neuromedin C,
somatostatin, LH-RH and Leu–Pro–Leu–Arg–Phe-NH2 alsoe to K562/ADM membrane vesicles
IC50 (lM)
-NH2 20.7 1.2
41.0 4.1
-M-NH2 29.9 4.0
25.8 2.5
12.1 1.3
-Y-P-R-G-N-H-W-A-V-G-H-L-M-NH2 3.6 0.5
83.0 16.5
-D-N-Q 47.5 6.2
NH2 10.7 1.7
10.1 0.5
32.0 0.4
ine binding by 50%. Data are expressed as the means S.E. of triplicate
tamic acid.
n ATPase activity. Panels A and B show ATPase stimulators and in-
m K562/ADM cells was immunoprecipitated with MRK-16. The P-
he ATPase assay. The ATPase activity in the presence or absence of
three independent membrane preparations (100%¼ 102 11 nmol/min/
–300 lM. Each point with bars represents the mean value and S.E. of
etermined by Bonferroni/Dunn test (two tail) (* P < 0:05, ** P < 0:01).
Fig. 2. Somatostatin transport by P-glycoprotein. (A) Time course of ATP-dependent uptake of somatostatin in membrane vesicles prepared from
K562/ADM and K562 cells. The uptake experiment was performed with membrane vesicles of K562/ADM and K562 cells in the presence or absence
of 5 mM ATP. Membrane vesicles were incubated with radio-labeled somatostatin at a ﬁnal concentration of 400 pM for the indicated time. Uptake
in the presence of 1 lM valspodar was measured. (B) Kinetic parameters of P-glycoprotein-mediated somatostatin uptake. Double reciprocal plot of
the uptake of somatostatin in membrane vesicles from K562/ADM cells. Initial transport rates were measured by incubation for 0.5 min. Reciprocal
values of the initial transport rates were plotted against 1/ATP concentrations. (C,D) Eﬀect of medium osmolality on somatostatin uptake by
membrane vesicles of K562/ADM. Transports of somatostatin was carried out in the transport buﬀer with diﬀerent osmolarlty (250 mM to 1 M
sucrose) in the presence of ATP. Each point and bar represent the mean value and S.E. of triplicate experiments.
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contrast, substance P slightly inhibited the basal ATPase ac-
tivity by 13% at 100 lM (Fig. 1B). Mastoparan inhibited the
basal ATPase activity in a concentration-dependent manner
(IC50 value was 1.3 0.3 lM, means S.E. of three experi-
ments) (Fig. 1B).
3.3. Somatostatin and substance P transport by P-glycoprotein
We carried out the P-glycoprotein-mediated transport assays
of somatostatin and substance P with plasma membrane ves-
icles containing signiﬁcant amounts of P-glycoprotein. Time
courses of somatostatin and substance P uptake in membrane
vesicles were shown in Fig. 2A and 3A, respectively. Vesicle-
associated peptides included the peptides that were bound to
and/or transported into vesicles. ATP increased the amounts of
vesicle-associated somatostatin and substance P in K562/
ADM, but not in K562 vesicles, suggesting that these peptides
were transported into the vesicles by an energy-dependent, P-
glycoprotein-mediated mechanism. The uptake of somato-statin was rapid, the maximal within 1 min being reached. On
the other hand, substance P uptake was slow and increasing
even after 2 min. In K562/ADM vesicles, ATP-dependent
transport was inhibited by 1 lM valspodar, a known MDR
reversal agent [26], which further supports the role of P-gly-
coprotein in the peptide transport. Initial rates of ATP-de-
pendent uptake of both somatostatin and substance P were
determined by incubating vesicles with various concentrations
of ATP (Fig. 2B and 3B). The uptake values followed simple
Michealis–Menten kinetics with apparent Km and Vmax values
of 49 lM and 44 fmol/min/mg P-glycoprotein for somatostatin
and 180 lM and 554 pmol/min/mg P-glycoprotein for sub-
stance P, respectively.
To measure the amount of transported peptides in the ves-
icle-associated ones, we examined the peptide transport in
various concentrations of sucrose. As shown in Fig. 2C and
3C, ATP-dependent somatostatin or substance P transport
decreased when osmolality increased from 250 mM to 1 M.
The values obtained from extrapolation to the inﬁnite high
Fig. 3. Substance P transport by P-glycoprotein. (A) Time course of ATP-dependent uptake of substance P in membrane vesicles prepared from
K562/ADM and K562 cells. Membrane vesicles were incubated with radio-labeled substance P at a ﬁnal concentration of 15 nM for the indicated
time. (B) Kinetic parameters of P-glycoprotein-mediated substance P uptake. Double reciprocal plot of the uptake of substance P in membrane
vesicles from K562/ADM cells. (C,D) Eﬀect of medium osmolality on substance P uptake by membrane vesicles of K562/ADM. Each point and bar
represent the mean value and S.E. of triplicate experiments.
Fig. 4. Somatostatin and substance P uptake in the membrane vesicles from human MDR1 transfected KB3-1 cells (GSV-2 cells). Membrane vesicles
from KB3-1 cells and GSV-2 cells were incubated with radio-labeled somatostatin at 400 pM or substance P at 15 nM for the indicated time. The
competition of peptide uptake was performed in the presence of excess amount of non-labeled peptide (10 lM). Each point and bar represent the
mean value and S.E. of triplicate experiments.
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75% of substance P associated with vesicles represents speciﬁc
transport into the intravesicular space (Fig. 2D and 3D). In
contrast, the amount of the peptides associated with the vesi-
cles showed no response to increased medium osmolality in the
absence of ATP. These results indicated that somatostatin and
substance P are transported by P-glycoprotein in an energy
dependent manner.
To exclude the possible involvement of other transporters
for bioactive peptide transport, an uptake experiment was also
performed with membrane vesicles prepared from human
MDR1-transfected KB3-1 cells (GSV-2 cells) or vector trans-
fected KB3-1 cells. In the presence of ATP, the uptake of so-
matostatin and substance P increased time-dependently in
GSV-2 cells, but not in KB3-1 cells (Fig. 4). In contrast, the
peptide uptake in GSV-2 cells was not observed in the absence
of ATP (data not shown). The ATP-dependent transport was
inhibited by 10 lM non-labeled bioactive peptides. Therefore,
the bioactive peptides competitively bound to the same binding
site(s) of P-glycoprotein for somatostatin and substance P.
3.4. Protease protection experiments of somatostatin or
substance P transport
To distinguish between simple binding and transport of the
peptides to membrane vesicles, a transport of the peptides was
analyzed by protease protection experiments. In the standard
condition with an ATP-regenerating system, somatostatin and
substance P were detectable in the fraction containing vesicles
(Fig. 5A, lanes 1 and 2). When a protease solution was added,
a major part of the peptides was not degraded (Fig. 5A, lane
3); however, the majority of peptides was proteolyzed by ad-
dition of detergent (Fig. 5A, lane 4). Furthermore, the vesicle
associated peptides were not extracted with high salt concen-
trations (data not shown). The results demonstrated that a
signiﬁcant population of peptides was transported into the
lumen of these vesicles. As compared with the standard con-
dition with an ATP-regenerating system (Fig. 5A, lane 3), ATP
depletion inhibited the peptide transport into the lumenFig. 5. Uptake of somatostatin and substance P across the plasma
membrane of vesicles from K562/ADM. After the uptake of substance
P, the vesicles were treated with trypsin in the presence or absence of
detergent. Trypsin mediated proteolysis was terminated by adding
protease inhibitors followed by the addition of Laemmli sample buﬀer.
Proteins were separated on SDS gels and transferred to Immobilon
sheets in order to detect peptides by immunoblot analysis. Lane 1,
untreated sample; lane 2, membranes treated with detergent; lane 3,
membranes treated with trypsin in the absence of detergent; lane 4,
membranes treated with trypsin in the presence of detergent. (A)
Incubation in the presence of an ATP-regenerating system. (B) Incu-
bation in the absence of ATP. (C) Incubation in the presence of an
ATP-regenerating system and 1 lM valspodar.(Fig. 5B, lane 3). In addition, an ATP-regenerating system
combined with 1 lM valspoder also showed inhibition of the
peptide transport (Fig. 5B and C, lane 3).4. Discussion
We investigated in the present study whether somatostatin,
substance P and certain bioactive peptides are able to interact
with P-glycoprotein. First, we showed that somatostatin,
substance P and nine bioactive peptides inhibited the ATP-
dependent vincristine binding eﬃciently with IC50 values of
micromolar concentrations, suggesting that they interact with
P-glycoprotein at a vincristine binding locus. Second, these
bioactive peptides stimulated or inhibited the basal P-glyco-
protein-ATPase activity at almost equal concentration range
for the inhibition of vincristine binding. Furthermore, we also
showed that somatostatin and substance P were transported
into plasma membrane vesicles prepared from K562/ADM
cells. The transports of somatostatin and substance P were
dependent on ATP and osmotically sensitive, and were in-
hibited by treatment of the vesicles with valspodar, a known
MDR reversal agent. These results clearly indicate that P-
glycoprotein transports both somatostatin and substance P.
Several peptide substrates for P-glycoprotein have been
reported to modulate its ATPase. Sarkadi et al. [27] showed
that the various biologically active hydrophobic peptide de-
rivatives, e.g., proteinase inhibitors, chemoattractants, iono-
phores, enkephalins and immunosuppressants, stimulated the
ATPase activity of P-glycoprotein in the vanadate-induced
trap method. In our study, the ATPase assay using P-glyco-
protein-MRK-16–Protein A–Sepharose immunocomplexes,
the ability of bioactive peptides to modulate P-glycoprotein-
ATPase was divided into two groups. While ﬁve peptides had
inhibitory eﬀects (substance P, GRP, dynorphin A, mastop-
aran and a-mating factor), other peptides had stimulatory
eﬀects (somatostatin, bombesin, neuromedin B, neuromedin
C, LH-RH and Leu–Pro–Leu–Arg–Phe-NH2) on the basal P-
glycoprotein-ATPase in a concentration-dependent manner
(Fig. 1A and B). Interestingly, while both somatostatin and
substance P were transported by P-glycoprotein in an ATP-
dependent manner (Fig. 2A and 3A, 5A and B, lane 3),
somatostatin stimulated the P-glycoprotein-ATPase and sub-
stance P inhibited it. Previously, we demonstrated that the
basal ATPase activity was inhibited by cyclosporine A, which
is known as a substrate for P-glycoprotein-mediated transport
[18,21]. In addition, all peptides used in our study inhibited
the ATP-dependent vincristine binding eﬃciently (Table 1).
Therefore, the eﬀects of the peptides on ATPase activity are
likely to be independent of their direct interactions with the
vincristine binding site(s) of P-glycoprotein or their transports
by P-glycoprotein. Recently, how drug transport by P-glyco-
protein is coupled to ATP hydrolysis was elucidated [28]. The
increase or decrease rate of ATP hydrolysis depends on the
distance between the LSGGQ sequence in one nucleotide-
binding domain (NBD) and the Walker A sequence in the
other NBD. Thus, it was speculated that the substrates that
stimulate P-glycoprotein-ATPase may bring the LSGGQ and
Walker A sites closer together so that ATP hydrolysis occurs
at a faster rate, while an inhibitory substrate, mastoparan,
may make both sites farther apart and/or reduce the rate of
ATP hydrolysis.
N. Uchiyama-Kokubu et al. / FEBS Letters 574 (2004) 55–61 61In addition, Oude Elferink and Zadina [29] demonstrated
that C-terminal amidation containing aromatic amino acids is
a crucial characteristic for peptides to be substrates. In their
report, membrane from MDR1-transfected cells transports the
synthetic opioid peptide DAMGO (Tyr–D-Ala–Gly–N-Me-
thyl–Phe–Gly-ol) and various other bioactive peptides in-
cluding substance P are good inhibitors of DAMGO transport.
In consistance with their ﬁndings, all peptides used in our
study (except dynorphin A and a-mating factor) have C-ter-
minal amidation, suggesting that these bioactive peptides also
have the characteristics for P-glycoprotein substrate. One re-
markable diﬀerence in the chemical structure between the in-
hibitors and the stimulators of P-glycoprotein-ATPase is that
the inhibitor such as mastoparan does not carry aromatic
amino acids, whereas other peptides do (Table 1). Lipophilic
peptides with aromatic amino acids may induce conforma-
tional changes of the drug-binding site in P-glycoprotein
leading to separation of the two NBDs.
The present ﬁndings raise the question whether the transport
of bioactive peptides by P-glycoprotein plays any signiﬁcant
physiological role. A signal sequence-dependent protein
translocation system is a well known secretory pathway of
peptides. Somatostatin-producing cells synthesized prosoma-
tostatin with a signal peptide, which was proteolytically pro-
cessed to mature somatostatin, and the mature hormone was
secreted by the cell [30]. Also, preprotachykinin was processed
into substance P by the same secretory pathway [31]. P-gly-
coprotein is expressed in hormone-secreting organs including
the adenohypophysis, adrenal cortex, placental trophoblasts
and pancreas [32,33], and supports our hypothesis that an al-
ternative pathway diﬀerent from the classical secretory path-
ways is present.
Furthermore, a role of P-glycoprotein in disposition of the
opioid peptide DPDPE ([D-penicillamine2;5]enkephalin) from
the brain was demonstrated by enhanced sensitivity of
Mdr1a(-/-) mice for this peptide [34]. Another interesting hy-
pothesis for P-glycoprotein’s physiological role is that P-gly-
coproteins expressed in the gastrointestinal tracts and kidney
are involved in peptide excretion mechanisms which are similar
to those in the blood–brain barrier. Although the main path-
way of downregulation of these bioactive peptide activities is
achieved by hydrolysis with peptidases [35], the disposition of
bioactive peptides by P-glycoprotein into the luminal space of
intestines may also contribute to the down regulation of their
signaling functions. Nevertheless, P-glycoprotein-mediated
transport might have a role in the elimination of bioactive
peptides that contribute to keep homeostatic balance in nor-
mal organs.References
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